Physician profile
Roberto Ramirez
NPI 1629669973
$4,516.94
in general payments reported to CMS, 2019-2025
11 companies · $913 in 2025
The $913 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $507 · 2022: $1,182 · 2023: $998 · 2024: $918 · 2025: $913.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,828.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,827.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $1,815.05 | 2021-2025 | Veltassa |
| Astrazeneca Pharmaceuticals Lp | $763.39 | 2021-2025 | Farxiga, Lokelma |
| Fresenius USA Marketing, INC. | $524.86 | 2021-2025 | Velphoro, Velphoro |
| Bayer Healthcare Pharmaceuticals INC. | $469.79 | 2022-2025 | |
| Horizon Therapeutics Plc | $423.56 | 2021-2023 | Krystexxa |
| Akebia Therapeutics INC | $199.28 | 2021-2022 | |
| Travere Therapeutics, INC. | $164.51 | 2023-2025 | |
| Aurinia Pharma U.S., INC. | $80.54 | 2021-2022 | |
| Apellis Pharmaceuticals, INC. | $33.36 | 2025 | Empaveli |
| Novo Nordisk INC | $22.86 | 2024 | Rivfloza |
| Glaxosmithkline, LLC. | $19.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberto Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.